
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Parexel, a leading provider of Clinical, Consulting and Commercial solutions announced its strategic collaboration with CluePoints, a provider of Risk-Based Study Execution (RBx) and Data Quality Oversight Software.
The addition of CluePoints’ CSM technology to facilitate the early identification of anomalous data, optimize on-site and central monitoring and reduce overall regulatory submission risk, coupled with Parexel’s extensive industry experience and RBM expertise, will help to meet the evolving needs of the industry and deliver safe and effective treatments to patients.
For further information on CluePoints' solutions, please visit www.cluepoints.com.
For further information on Parexel, please visit www.parexel.com.






